14 May 2026
14 May 2026
The assay enables ChLIA measurement of testosterone markers, delivering diagnostic capabilities for suspected male hypogonadism.
The trial builds on findings from the FLIP-1 Phase I study, which was conducted at the March of Dimes PRC.
The approval covers all 27 EU member states, Liechtenstein, Norway, and Iceland.
The CE mark was granted based on data from retrospective studies in real-world early cognitive decline population.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
